



# Sales of anti-cancer medicines; China, Indonesia, Kazakhstan, Malaysia, Philippines and Thailand

## Citation

Ferrario, Alessandra, Peter Stephens, Guan Xiaodong, Dennis Ross-Degnan, and Anita Wagner. 2020. Sales of anti-cancer medicines; China, Indonesia, Kazakhstan, Malaysia, Philippines and Thailand. *Bull World Health Organ* 98, no. 7: 467–474.

## Permanent link

<https://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37366554>

## Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Open Access Policy Articles, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#OAP>

## Share Your Story

The Harvard community has made this article openly available.  
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

## Supplementary material

### Sales of anti-cancer medicines in China, Indonesia, Kazakhstan, Malaysia, Philippines and Thailand from 2007 to 2017

Alessandra Ferrario<sup>1\*</sup>, Peter Stephens<sup>2</sup>, Xiaodong Guan<sup>3</sup>, Dennis Ross-Degnan<sup>1</sup>, and Anita Wagner<sup>1</sup>

<sup>1</sup>Harvard Medical School and Harvard Pilgrim Healthcare Institute, Boston, United States

<sup>2</sup>IQVIA, London, United Kingdom

<sup>3</sup>Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China

#### List of medicines excluded in the study

Reason for exclusion: Supportive medications for side-effects

- allopurinol
- calcium folinate
- filgrastim
- mesna
- zoledronic acid

\*Co-medications with various other non-cancer uses

- dexamethasone
- hydrocortisone
- methylprednisolone
- □ prednisolone
- Methotrexate

Note: \*These exclusions are based on the listing of these medications in other therapeutic classes in the WHO EML 2017 besides sections 8.2 or 8.3

Source of list of medicines: Source: WHO Model List of Essential Medicines. 20th List (March 2017) (Amended August 2017). Available at:

<https://www.who.int/medicines/publications/essentialmedicines/en/>

**Supplementary table 1: Inclusion of WHO 2017 EML-listed medicines in national EML**

<b>List of anti-cancer medicines in the WHO EML 2017</b>	<b>China 2017</b>	<b>Indonesia 2017</b>	<b>Kazakhstan 2013-2015</b>	<b>Malaysia 2016</b>	<b>Philippines 2017</b>	<b>Thailand 2017</b>
asparaginase	√	√	√	√	√	√
bleomycin	√	√	√	√	√	√
chlorambucil	√	√	√	√	√	√
cisplatin	√	√	√	√	√	√
cyclophosphamide	√	√	√ (IV)	√	√	√
cytarabine	√	√	√	√	√	√
dacarbazine	√	√	√	√	√	√
dactinomycin	√	√		√	√	√
daunorubicin	√	√	√	√		
doxorubicin	√	√	√	√	√	√
etoposide	√	√	√	√	√	√
fluorouracil	√	√	√	√	√	√
mercaptopurine	√	√	√	√	√	√
procarbazine				√		√
vinblastine		√	√	√	√	
vincristine	√	√	√	√	√	√
tamoxifen		√	√	√		√
bendamustine		√		√		
nilotinib		√	√	√		√
dasatinib	√					√
oxaliplatin	√	√	√	√	√	√
imatinib	√	√	√	√	√	√
trastuzumab	√	√	√	√	√	√
capecitabine	√	√	√	√	√	√
□ leuprorelin		√	√	√	√	√
rituximab	√	√	√	√	√	*
irinotecan	√	√	√	√	√	
docetaxel	√	√	√	√	√	√
gemcitabine	√	√	√	√	√	√
□ anastrozole		√	√	√		
all-trans retinoid acid (ATRA) or tretinoin			√	√		√
□ bicalutamide		√	√	√	√	
vinorelbine	√	√	√	√		
paclitaxel	√	√	√	√	√	√
fludarabine	√	√	√	√		
carboplatin	√	√	√	√	√	√

ifosfamide	√	√	√	√	√	√
hydroxycarbamide	√	√	√	√		√
tioguanine	√			√		√

## Sources

### China

Notice of the Ministry of Human Resources and Social Security on Issuing the National Reimbursement Drug List (Version 2017) of the Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance. Ministry of Human Resources and Social Security; Available from:

[http://www.gov.cn/xinwen/2018-10/10/content\\_5328891.htm](http://www.gov.cn/xinwen/2018-10/10/content_5328891.htm)

### Indonesia

Formularium Nasional, 2017

[http://hukor.kemkes.go.id/uploads/produk\\_hukum/KMK\\_No.\\_HK\\_.01\\_.07-MENKES-659-2017\\_ttg\\_Formularium\\_Nasional\\_.pdf](http://hukor.kemkes.go.id/uploads/produk_hukum/KMK_No._HK_.01_.07-MENKES-659-2017_ttg_Formularium_Nasional_.pdf) (accessed 6 April 2020)

### Kazakhstan

[Directory of prices of medicines purchased within the guaranteed amount of free medical care, 2013]

<http://www.druginfo.kz/index.php/ru/dlya-spetsialistov-v-oblasti-zdravookhraneniya/spravochniki-lekarstvennykh-sredstv> (accessed 2 April 2020)

Cherny NI, Sullivan R, Torode J, Saar M, Eniu A, ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe, *Ann Oncol.* 2017 Nov; 28(11): 2633–2647.

### Malaysia

Ministry of Health Medicines Formulary. <https://www.pharmacy.gov.my/v2/en/documents/ministry-health-medicines-formulary-mohmf.html> (accessed 6 April 2020)

Asrul Akmal Shafie, Haarathi Chandriah, Access to cancer drugs: Are we meeting the needs of Malaysian? *Journal of Cancer Policy.* 2017; 13: 30–32

## Philippines

Department of Health Pharmaceutical Division, Philippine National Formulary, 8<sup>th</sup> Edition, 2017;  
<http://caro.doh.gov.ph/wp-content/uploads/2018/04/PNF-8th-edition.pdf> (accessed 6 April 2020)

## Thailand

National list of essential medicines – 2017. Bangkok: Food and Drug Administration Thailand; 2017.  
<http://www.ratchakitcha.soc.go.th/DATA/PDF/2560/E/119/27.PDF> (accessed 5 April 2020)

\*Rituximab is included in the 2018 Thai National list of essential medicines